Mechanisms dissection of the combination GRS derived from ShengMai preparations for the treatment of myocardial ischemia/reperfusion injury

J Ethnopharmacol. 2021 Jan 10:264:113381. doi: 10.1016/j.jep.2020.113381. Epub 2020 Sep 15.

Abstract

Ethnopharmacological relevance: Recently, a new drug combination GRS comprising ginsenoside Rb1 (G-Rb1), ruscogenin (R-Rus) and schisandrin (S-SA) was screened based on ShengMai preparations, which exhibited a prominent cardioprotective effects against myocardial ischemia/reperfusion (MI/R) injury.

Aim of the study: To investigate their systemic and individual mechanism of each compound in combination GRS.

Materials and methods: The mice model of MI/R and hypoxia/reoxygenation (H/R)-induced cardiomyocytes injury were performed to explore the respective characteristics of each compound in GRS against myocardial injury.

Results: Each component in the combination GRS attenuated MI/R injury as evidenced by decreased myocardial infarct size, ameliorated histological features, and improved biochemical indicators. Meanwhile, ingredient G, R and S in combination also individually performed a significant decrease of apoptotic index in MI/R mice and H/R-induced cardiomyocytes injury. Mechanistically, component G in GRS could markedly increase the ATP content in cardiomyocytes through activation of AMPKα phosphorylation. Interestingly, the anti-apoptotic actions of G were profoundly attenuated by knockdown of AMPKα, while no alteration was observed on composition R and S. Moreover, component R in GRS significantly reduced the IL-6 and TNF-α mRNA expression, as well as the content of IL-6 via the modulation of NF-κB signaling pathway. Further, component S exhibited the most powerful anti-oxidative capacity in GRS and remarkably decreased the production of MDA and ROS, and potential mechanisms might at least in part through activating the Akt-14-3-3 signaling pathway and inhibiting the phosphorylation of Bad and ERK1/2.

Conclusions: Our results indicated that the respective mechanism of each compound in combination GRS against MI/R injury might closely associated with energy metabolism modulation, suppression of inflammation and oxidative stress.

Keywords: 23915); 441893); 441922); Ajor chemical compounds studied in this article; Anti-inflammation; Antioxidation; Energy modulation; Ginsenoside Rb1 (PubChem CID; Multiple pathways; Myocardial ischemia/reperfusion injury; Ruscogenin (PubChem CID; Schisandrol a (PubChem CID; Shengmai combination GRS.

MeSH terms

  • Animals
  • Cell Line
  • Cell Survival / drug effects
  • Cell Survival / physiology
  • Cyclooctanes / administration & dosage*
  • Cyclooctanes / isolation & purification
  • Drug Combinations
  • Drugs, Chinese Herbal / administration & dosage*
  • Drugs, Chinese Herbal / isolation & purification
  • Ginsenosides / administration & dosage*
  • Ginsenosides / isolation & purification
  • Inflammation Mediators / antagonists & inhibitors
  • Inflammation Mediators / metabolism
  • Lignans / administration & dosage*
  • Lignans / isolation & purification
  • Male
  • Mice
  • Mice, Inbred ICR
  • Myocardial Reperfusion Injury / drug therapy*
  • Myocardial Reperfusion Injury / metabolism
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Polycyclic Compounds / administration & dosage*
  • Polycyclic Compounds / isolation & purification
  • Rats
  • Spirostans / administration & dosage*
  • Spirostans / isolation & purification
  • Treatment Outcome

Substances

  • Cyclooctanes
  • Drug Combinations
  • Drugs, Chinese Herbal
  • Ginsenosides
  • Inflammation Mediators
  • Lignans
  • Polycyclic Compounds
  • Spirostans
  • fructus schizandrae, radix ginseng, radix ophiopogonis drug combination
  • ginsenoside Rb1
  • ruscogenin
  • schizandrin